What is the role of apalutamide (Erleada) in the treatment of hormone-refractory prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

Answer

Another androgen receptor–targeting therapy, apalutamide (Erleada), was approved in 2018 for use in nonmetastatic CRPC. The FDA based its new approval on safety and efficacy data from the phase 3 SPARTAN (Selective Prostate Androgen Receptor Targeting With ARN-509) trial. Median metastasis-free survival, which was the primary trial endpoint, was 40.5 months in the apalutamide group (n=806) as compared with 16.2 months in the placebo group (n=401). That translated into a 72% reduction in the relative risk for metastasis or death with apalutamide (HR, 0.28; 95% CI 0.23 - 0.35; P < 0.001). All participants also received hormone therapy, either gonadotropin-releasing hormone analogue therapy or surgical castration. [50]

Apalutamide was also approved for mCSPC in September 2019. Approval was based on the phase 3 TITAN trial (n = 1052)j, in which apalutamide plus ADT significantly extended overall survival compared with placebo plus ADT (HR=0.67; 95% CI, 0.51-0.89; P = 0.0053). Progression-free survival was also significantly improved in the apalutamide group (HR=0.48; 95% CI, 0.39-0.60; P< 0.0001). [51]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!